Paper Details

  1. Home
  2. Paper Details

Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters.

Author: AdachiTomohiko, KanematsuTakashi, KitasatoAmane, KurokiTamotsu, MishimaTakehiro, TajimaYoshitsugu, TsuneokaNoritsugu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Etodolac, a medication used to relieve pain and inflammation, may help to prevent pancreatic cancer in hamsters. Etodolac was found to reduce the incidence of pancreatic cancer in hamsters exposed to a known cancer-causing agent.
Paper Details　
Original Abstract of the Article :
The present study was designed to determine whether etodolac, a selective cyclooxygenase-2 inhibitor, prevents chemically induced intraductal papillary carcinoma (IPC) in the main pancreatic duct of hamsters. Hamsters were subjected to cholecystoduodenostomy with dissection of the distal end of the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/carcin/bgn047

データ提供：米国国立医学図書館（NLM）

Chemoprevention of Pancreatic Cancer: A New Oasis in the Desert of Cancer Research

Pancreatic cancer is a particularly aggressive and difficult-to-treat disease. This study explores the potential of a selective cyclooxygenase-2 inhibitor, etodolac, in preventing chemically-induced pancreatic cancer in hamsters. The researchers found that etodolac significantly reduced the incidence of intraductal papillary carcinoma (IPC), a precursor to pancreatic cancer, suggesting a potential role for COX-2 inhibitors in cancer prevention.

Etodolac: A Potential Oasis in the Desert of Pancreatic Cancer Prevention

The study findings offer a glimmer of hope in the desert of pancreatic cancer research. The researchers demonstrate that etodolac, a COX-2 inhibitor, effectively reduced the incidence of IPC in hamsters, suggesting a potential role for COX-2 inhibitors in cancer prevention. This research opens new avenues for exploring chemoprevention strategies in the fight against pancreatic cancer.

Navigating the Desert of Cancer Prevention

This research highlights the importance of exploring new approaches to cancer prevention. The findings suggest that targeting COX-2 may offer a promising strategy for preventing pancreatic cancer. This research encourages continued investigation into the potential of COX-2 inhibitors as a chemoprevention tool, seeking new oases of knowledge and therapeutic solutions in the desert of cancer research.

Dr.Camel's Conclusion

The desert of pancreatic cancer research is vast and unforgiving, but this study offers a glimmer of hope. The findings suggest that etodolac, a COX-2 inhibitor, may offer a promising strategy for preventing this aggressive disease. This research encourages continued exploration of this potential oasis in the desert of cancer prevention, seeking new avenues for combating this deadly disease.

Date :
  1. Date Completed 2008-04-28
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

18296437

DOI: Digital Object Identifier

10.1093/carcin/bgn047

Related Literature

Article Analysis
・Effects of etodolac
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.